Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries to 2020 - Siouxland News - KMEG 14 and FOX 44

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries to 2020

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Feb. 12, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/x4z6dv/acute

) has announced the addition of the

"Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries to 2020"

report to their offering.


(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials).



The acute lymphocytic/lymphoblastic leukemia therapeutics market is valued at an estimated $2,777.2 million in 2013 and is expected to reach $3,780.3 million by 2020, at a CAGR of 4.0% from 2015 to 2020.



Presently, the acute lymphocytic/lymphoblastic leukemia market is driven by factors such as the increasing incidence rate of ALL cases, development of innovative therapies such as multi-drug regimens, and continuous efforts of pharmaceutical companies to offer superior-quality drugs. Such improved regimens and drugs have shown significant results in the overall survival rate.



The overall growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market is largely challenged by the patent expiration of existing drugs. Arranon (nelarabine), a monotherapy drug, lost its patent in February 2013, whereas, Clolar (clofarabine) is due for patent expiration in 2018.



Some of the major players in this market include ERYtech Pharma (France), Talon Therapeutic, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), Pfizer, Inc. (U.S.), and Genzyme Corporation (U.S.).



Key Topics Covered:



1 Introduction

2 Executive Summary

3 Market Overview

4 Acute Lymphocytic Leukemia Market Dynamics

5 Leukemia Product Market

6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase III)

7 Geographic Analysis

8 Company Profiles

Companies Mentioned:

  • Erytech Pharma
  • Genzyme Corporation
  • Glaxosmithkline Plc
  • Pfizer Inc
  • Sigma-Tau Pharmaceuticals, Inc
  • Talon Therapeutics, Inc (Spectrum Pharmaceuticals, Inc)

For more information visit http://www.researchandmarkets.com/research/x4z6dv/acute

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

Siouxland News
100 Gold Circle
Dakota Dunes, SD 57049

Main Phone: 712-277-3554
Main Fax: 712-255-5250
Email: webmaster@siouxlandnews.com

Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and Sinclair Communications, LLC. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.